Literature DB >> 34729862

Effect of high-flow nasal cannula oxygen therapy on exercise tolerance in patients with idiopathic pulmonary fibrosis: A randomized crossover trial.

Jumpei Harada1,2, Kazuma Nagata3, Takeshi Morimoto4,5, Kentaro Iwata1,2, Atsushi Matsunashi3, Yuki Sato3, Ryo Tachikawa3, Akira Ishikawa2, Keisuke Tomii3.   

Abstract

BACKGROUND AND
OBJECTIVE: Exercise capacity in idiopathic pulmonary fibrosis (IPF) is limited by exercise-induced hypoxaemia. This study aimed to examine the effect of high-flow nasal cannula oxygen therapy (HFNC) on exercise tolerance in patients with IPF.
METHODS: We conducted a single-centre, open-label, randomized crossover trial to compare HFNC and Venturi mask (VM) therapy in terms of exercise tolerance. Patients underwent constant-load symptom-limited exercise testing at 80% peak work rate with HFNC or a VM in a randomized order. The settings were 60 L/min and a 50% fraction of inspired oxygen (FiO2 ) for HFNC and 12 L/min and 50% FiO2 for VM. The primary outcome was endurance time, and the secondary outcomes were heart rate (HR), percutaneous oxygen saturation (SpO2 ), dyspnoea and leg fatigue, as determined by the modified Borg Scale at the isotime and endpoint, and the level of comfort while using the devices.
RESULTS: Twenty-four participants (75.0% men; age, median [interquartile range]: 77.5 [68.8-83.0] years) were enrolled. Compared with VM, HFNC significantly improved the endurance time (647.5 s [454.0-1014.8] vs. 577.5 s [338.0-861.5]), minimum SpO2 (96.0% [95.0-98.0] vs. 94.0% [92.8-96.0]) and leg fatigue at the isotime (3.0 [1.6-4.0] vs. 5.0 [3.0-6.3]) and endpoint (4.0 [2.8-5.0] vs. 5.0 [3.8-6.3]). Differences in maximum HR, dyspnoea at the isotime and endpoint and comfort were non-significant between HFNC and VM therapy.
CONCLUSION: HFNC increased exercise tolerance in patients with stable IPF experiencing exercise-induced hypoxaemia.
© 2021 Asian Pacific Society of Respirology.

Entities:  

Keywords:  endurance time; exercise tolerance; exercise-induced hypoxaemia; high-flow nasal cannula oxygen therapy; idiopathic pulmonary fibrosis; leg fatigue; rehabilitation

Mesh:

Substances:

Year:  2021        PMID: 34729862     DOI: 10.1111/resp.14176

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  2 in total

Review 1.  ERS International Congress 2021: highlights from the Respiratory Clinical Care and Physiology Assembly.

Authors:  Thomas Gille; Pradeesh Sivapalan; Georgios Kaltsakas; Shailesh B Kolekar; Matthew Armstrong; Rachel Tuffnell; Rachael A Evans; Guido Vagheggini; Luiza Helena Degani-Costa; Cláudia Vicente; Nilakash Das; Vitalii Poberezhets; Camille Rolland-Debord; Sam Bayat; Ioannis Vogiatzis; Frits M E Franssen; Hilary Pinnock; Lowie E G W Vanfleteren
Journal:  ERJ Open Res       Date:  2022-05-23

Review 2.  IPF Respiratory Symptoms Management - Current Evidence.

Authors:  Piotr Janowiak; Amelia Szymanowska-Narloch; Alicja Siemińska
Journal:  Front Med (Lausanne)       Date:  2022-07-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.